EGFR and neoplasm: Future directions should emphasize rational design of dual-targeting nanocarriers, employing ligands for both BBB penetration (e.g., angiopep-2, transferrin, lactoferrin) and tumor specificity (e.g., RGD peptides, EGFR, folate).